BMO Capital Starts Merck (MRK) at Market Perform

Merck (MRK) Stops Dosing in Phase 2 Trial of MK-8507 and Islatravir for the Treatment of HIV-1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced an update regarding the Phase 2 IMAGINE-DR clinical trial (MK-8507-13), which is evaluating the investigational combination of MK-8507, a non-nucleoside reverse transcriptase inhibitor, and islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, as a once-weekly oral treatment for HIV-1 infection. MK-8507 and islatravir, alone and in combination, are investigational and not approved for use.

Decreases in total lymphocyte and CD4+ T-cell counts were observed in study participants randomized to receive ISL+MK-8507. A review by the external Data Monitoring... More

Merck's (MRK) KEYTRUDA Granted FDA Approval as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Mercks anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. The approval is based on data from the pivotal Phase 3 KEYNOTE-564 trial, in which KEYTRUDA demonstrated a statistically significant improvement in disease-free survival (DFS), reducing the risk of disease recurrence or death by 32% (HR=0.68 [95% CI, 0.53-0.87];... More

Acceleron Pharma (XLRN) Climbs 3.3% After Merck (MRK) Announces Expiration of HSR Waiting Period for Acquisition

Acceleron Pharma (NASDAQ: XLRN) Climbs 3.3% After Merck (NYSE: MRK) Announces Expiration of HSR Waiting Period for Acquisition

Merck (MRK) Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma (XLRN)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Mercks pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) expired at 11:59 p.m., Eastern Time, on Nov. 16, 2021.

As previously announced on Oct. 12, 2021, Merck commenced, through a subsidiary, Astros Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Acceleron, for $180 in cash, without interest and less any required tax... More

Merck (MRK) and Ridgeback to Report Phase 3 Data for Molnupiravir

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that new Phase 3 data for molnupiravir, an investigational oral COVID-19 antiviral medicine, will be presented as a late-breaking poster (#LB-5319) at the American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting taking place virtually from Nov. 17-21. Poster data will be available on Wednesday, Nov. 17 at 9 a.m. ET and presented during Poster Session C from 11 a.m.-12:30 p.m. ET on Saturday, Nov. 20.

The presentation will include data from the molnupiravir clinical... More